Outset Medical, INC. (OM) — SEC Filings

Q: What are the key financial highlights for Outset Medical, INC.?

Key financial highlights for Outset Medical, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Outset Medical, INC.?

Key executives at Outset Medical, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Outset Medical, INC. stock?

Risk factors for Outset Medical, INC. (OM) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Outset Medical, INC.?

Forward-looking statements and predictions from Outset Medical, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Outset Medical, INC.. Recent 10-Q filing on Nov 10, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Outset Medical, INC. on SEC EDGAR

Overview

Outset Medical, INC. (OM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Outset Medical, Inc. (OM) reported a net loss of $17.8 million for the three months ended September 30, 2025, an improvement from a $27.9 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $62.2 million, significantly reduced from $102.3 milli

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Outset Medical, INC. is neutral.

Filing Type Overview

Outset Medical, INC. (OM) has filed 6 10-Q, 21 8-K, 3 DEF 14A, 2 10-K, 14 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

Outset Medical Narrows Losses, Boosts Liquidity with New Financing — 10-Q · Nov 10, 2025 Risk: medium
Outset Medical, Inc. (OM) reported a net loss of $17.8 million for the three months ended September 30, 2025, an improvement from a $27.9 million net loss in th
Outset Medical Narrows Q2 Loss to $30.2M on Strong Consumables Growth — 10-Q · Aug 7, 2025 Risk: high
Outset Medical, Inc. reported a net loss of $30.2 million for the quarter ended June 30, 2025, a slight improvement from the $32.5 million net loss in the prior
Outset Medical Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
Outset Medical, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements an
Outset Medical Files 8-K: Director Changes, Officer Appointments — 8-K · Jun 3, 2025 Risk: medium
Outset Medical, Inc. filed an 8-K on May 30, 2025, reporting on several key events. These include the departure of a director, the election of new directors, an
Outset Medical Files 8-K on Officer/Director Changes — 8-K · May 14, 2025 Risk: medium
Outset Medical, Inc. filed an 8-K on May 14, 2025, reporting on events as of May 10, 2025. The filing covers the departure of directors or certain officers, the
Outset Medical Files 10-Q for Q1 2025 — 10-Q · May 8, 2025 Risk: medium
Outset Medical, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including common stock and preferred s
Outset Medical Files 8-K on Financials — 8-K · May 7, 2025 Risk: low
Outset Medical, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and e
Outset Medical Files DEF 14A Detailing Executive Compensation — DEF 14A · Apr 11, 2025 Risk: medium
Outset Medical, Inc. filed a DEF 14A on April 11, 2025, for the fiscal year ending June 2, 2025. The filing details executive compensation and equity awards gra
Outset Medical Files 8-K on Corporate Changes — 8-K · Mar 20, 2025 Risk: low
On March 20, 2025, Outset Medical, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles of incorpo
Outset Medical Files 8-K — 8-K · Mar 18, 2025 Risk: low
Outset Medical, Inc. filed an 8-K on March 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is based in San Jos
Outset Medical Files 8-K with Corporate Updates — 8-K · Mar 11, 2025 Risk: low
On March 7, 2025, Outset Medical, Inc. filed an 8-K report detailing amendments to its articles of incorporation or bylaws, other events, and financial statemen
Outset Medical Submits Matters to Security Holders — 8-K · Mar 6, 2025 Risk: low
On March 5, 2025, Outset Medical, Inc. filed an 8-K report to announce that it submitted matters to a vote of its security holders. The filing does not disclose
10-K Filing — 10-K · Feb 28, 2025
Outset Medical Faces Delisting Concerns — 8-K · Feb 26, 2025 Risk: high
Outset Medical, Inc. filed an 8-K on February 26, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing also covers ot
Outset Medical Files 8-K on Financials — 8-K · Feb 19, 2025 Risk: low
Outset Medical, Inc. filed an 8-K on February 19, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhi
Outset Medical Files Definitive Proxy Statement — DEF 14A · Feb 4, 2025 Risk: low
Outset Medical, Inc. filed its definitive proxy statement (DEF 14A) on February 4, 2025, for its annual meeting on March 5, 2025. The filing provides informatio
Outset Medical Files 8-K for Bylaw Amendments and Exhibits — 8-K · Jan 24, 2025 Risk: low
Outset Medical, Inc. filed an 8-K on January 24, 2025, reporting events as of January 23, 2025. The filing primarily concerns amendments to its articles of inco
Outset Medical Files 8-K: Agreement Termination & Financial Obligation — 8-K · Jan 8, 2025 Risk: medium
Outset Medical, Inc. announced on January 7, 2025, the termination of a material definitive agreement and the creation of a direct financial obligation. The com
Outset Medical Files 8-K with Material Agreements — 8-K · Jan 6, 2025 Risk: medium
On January 3, 2025, Outset Medical, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations, unregister
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
Outset Medical Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
Outset Medical, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial da
Outset Medical Files 8-K for Financial Reporting — 8-K · Nov 6, 2024 Risk: low
Outset Medical, Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements a
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
Outset Medical Faces Listing Rule Concerns — 8-K · Sep 27, 2024 Risk: high
Outset Medical, Inc. filed an 8-K on September 27, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The filing indicates a
SC 13G/A Filing — SC 13G/A · Sep 10, 2024
SC 13G/A Filing — SC 13G/A · Sep 9, 2024
SC 13G/A Filing — SC 13G/A · Sep 5, 2024
SC 13G Filing — SC 13G · Aug 23, 2024
Outset Medical Appoints New CFO, Reports Executive Compensation — 8-K · Aug 16, 2024 Risk: medium
Outset Medical, Inc. announced on August 15, 2024, the departure of its Chief Financial Officer, John L. Ruff, effective August 15, 2024. The company also annou
Outset Medical Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
Outset Medical, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter
Outset Medical Files 8-K on Financials — 8-K · Aug 7, 2024 Risk: low
Outset Medical, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements and
SC 13G/A Filing — SC 13G/A · Jul 8, 2024
Outset Medical Files 8-K on Shareholder Vote Matters — 8-K · May 30, 2024 Risk: low
Outset Medical, Inc. filed an 8-K on May 30, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The filing does not detail t
Outset Medical, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
Outset Medical, Inc. (OM) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Outset Medical, Inc. filed a 10-Q report for the period ending March 31,
Outset Medical Files 8-K with Financials and Officer Changes — 8-K · May 8, 2024 Risk: medium
Outset Medical, Inc. filed an 8-K on May 8, 2024, reporting on results of operations, financial condition, and changes in its board and officer composition. The
Outset Medical Files 8-K — 8-K · May 6, 2024 Risk: low
Outset Medical, Inc. filed an 8-K on May 6, 2024, to report other events and financial statements. The filing does not contain specific financial details or sig
Outset Medical, Inc. Files DEF 14A with Executive Compensation Details — DEF 14A · Apr 11, 2024 Risk:
Outset Medical, Inc. (OM) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. The filing is a DEF 14A from Outset Medical, Inc., dated April 11, 2
SC 13G/A Filing — SC 13G/A · Apr 10, 2024
Outset Medical Appoints New CFO, Announces Compensation — 8-K · Mar 13, 2024 Risk: medium
Outset Medical, Inc. announced on March 8, 2024, the appointment of Richard R. Thomas as Chief Financial Officer, effective March 11, 2024. Thomas will receive
Outset Medical, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 21, 2024 Risk:
Outset Medical, Inc. (OM) filed a Annual Report (10-K) with the SEC on February 21, 2024. Outset Medical, Inc. filed its 2023 Form 10-K on February 21, 2024. Th
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
FMR LLC & Abigail Johnson Hold 14.075% Stake in Outset Medical — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Outset Medical, Inc. (OM) through an SC 13G
Morgan Stanley Discloses Passive Stake in Outset Medical (OM) — SC 13G · Feb 9, 2024 Risk: low
Morgan Stanley, a major financial institution, filed an SC 13G on February 9, 2024, indicating its ownership of Outset Medical, Inc. (OM) common stock as of Dec
BlackRock Amends Outset Medical Stake, Maintains Passive Investment — SC 13G/A · Jan 26, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating its ownership in Outset Medical, Inc. (NASDAQ: OM) as of December 31, 2023. This
JPMorgan Amends Outset Medical Stake, Files SC 13G/A — SC 13G/A · Jan 23, 2024
JPMorgan Chase & Co. filed an amended Schedule 13G/A on January 23, 2024, indicating a change in their beneficial ownership of Outset Medical, Inc. common stock

Risk Profile

Risk Assessment: Of OM's 31 recent filings, 3 were flagged as high-risk, 12 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Outset Medical, INC.'s most recent 10-Q filing (Nov 10, 2025):

Revenue: $29.4M
Net Income: -$17.8M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $182.0M
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

John L. Ruff
Leslie Ryan
Richard R. Thomas
Abigail P. Johnson

Industry Context

The medical device industry, particularly in renal care, is characterized by significant innovation, stringent regulatory oversight, and intense competition. Companies like Outset Medical are focused on developing advanced technologies to improve patient outcomes and reduce healthcare costs. The shift towards home dialysis and more efficient treatment modalities presents opportunities, but also requires substantial investment in R&D and market penetration.

Top Tags

corporate-governance (9) · financial-reporting (7) · 10-Q (4) · financials (4) · institutional-ownership (4) · Medical Devices (3) · filing (3) · 8-k (3) · sec-filing (3) · Outset Medical (3)

Key Numbers

Total Revenue (Q3 2025): $29.4M — Increased from $28.7M in Q3 2024, showing modest growth.
Net Loss (Q3 2025): $17.8M — Reduced from $27.9M in Q3 2024, indicating improved operational efficiency.
Net Loss (YTD Sept 2025): $62.2M — Significantly reduced from $102.3M in YTD Sept 2024.
Accumulated Deficit: $1.2B — As of September 30, 2025, highlighting historical losses.
Total Cash & Investments: $182.0M — As of September 30, 2025, providing liquidity for the next 12 months.
Series A Preferred Stock Proceeds: $172.7M — Gross proceeds from private placement in Q1 2025, bolstering capital.
Perceptive Term Loan: $100M — New debt financing secured in January 2025.
Reverse Stock Split: 15-for-one — Effected in March 2025, impacting share count and per-share metrics.
Net Cash Used in Operating Activities (YTD Sept 2025): $36.8M — Reduced from $99.8M in YTD Sept 2024, showing improved cash burn.
Common Shares Outstanding (in thousands): 17,809 — As of September 30, 2025, post-reverse stock split.
Net Loss for Q2 2025: $30.2 million — Improved from $32.5 million net loss in Q2 2024
Revenue for Q2 2025: $36.5 million — Increased by 12.3% from $32.5 million in Q2 2024
Consumables Product Revenue for Q2 2025: $21.3 million — Increased by 15.8% from $18.4 million in Q2 2024
Accumulated Deficit as of June 30, 2025: $1.1 billion — Indicates significant historical losses
Draw on Perceptive Credit Agreement: $15.0 million — Occurred in January 2025, increasing debt

Forward-Looking Statements

{"claim":"FMR LLC will maintain a significant, passive ownership stake in Outset Medical, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
{"claim":"Morgan Stanley will maintain its passive stake in Outset Medical for the foreseeable future.","entity":"Morgan Stanley","targetDate":"Q4 2024","confidence":"medium"}

Related Companies

BAX · FMS

Frequently Asked Questions

What are the latest SEC filings for Outset Medical, INC. (OM)?

Outset Medical, INC. has 50 recent SEC filings from Jan 2024 to Nov 2025, including 21 8-K, 14 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of OM filings?

Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Outset Medical, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Outset Medical, INC. (OM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Outset Medical, INC.?

Key financial highlights from Outset Medical, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for OM?

The investment thesis for OM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Outset Medical, INC.?

Key executives identified across Outset Medical, INC.'s filings include John L. Ruff, Leslie Ryan, Richard R. Thomas, Abigail P. Johnson.

What are the main risk factors for Outset Medical, INC. stock?

Of OM's 31 assessed filings, 3 were flagged high-risk, 12 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Outset Medical, INC.?

Recent forward-looking statements from Outset Medical, INC. include guidance on {"claim":"FMR LLC will maintain a significant, passive ownership stake in Outset Medical, Inc. for the foreseeable futur and 1 other predictions.